Related references
Note: Only part of the references are listed.PP2A and Its Inhibitors in Helper T-Cell Differentiation and Autoimmunity
Mohd Moin Khan et al.
FRONTIERS IN IMMUNOLOGY (2022)
SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback
S. Liu et al.
CANCER LETTERS (2022)
Mechanism Analysis of LINC00665 and Its Peptides CIP2A-BP in Hepatocellular Carcinoma
Yi-Ran Li et al.
FRONTIERS IN GENETICS (2022)
CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
Melani Luque et al.
JOURNAL OF CLINICAL MEDICINE (2022)
(+)-Cyanidan-3-ol inhibits epidermoid squamous cell carcinoma growth via inhibiting AKT/mTOR signaling through modulating CIP2A-PP2A axis
Jitender Monga et al.
PHYTOMEDICINE (2022)
Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization
Jianying Zhang et al.
FRONTIERS IN ONCOLOGY (2022)
MTBP and MYC: A Dynamic Duo in Proliferation, Cancer, and Aging
Brian C. Grieb et al.
BIOLOGY-BASEL (2022)
CIP2A regulates MYC translation (via its 5′UTR) in colorectal cancer
S. Denk et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2021)
MYC as a target for cancer treatment
Michael J. Duffy et al.
CANCER TREATMENT REVIEWS (2021)
Integrative assessment of CIP2A overexpression and mutational effects in human malignancies identifies possible deleterious variants
Mohammad M. Tarek et al.
COMPUTERS IN BIOLOGY AND MEDICINE (2021)
2,5-Dimethyl Celecoxib Inhibits Proliferation and Cell Cycle and Induces Apoptosis in Glioblastoma by Suppressing CIP2A/PP2A/Akt Signaling Axis
Dezheng Gao et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2021)
Growth Factor Deregulation and Emerging Role of Phosphatases in Diabetic Peripheral Artery Disease
Clement Mercier et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Multipanel assay of 17 tumor-associated antibodies for serological detection of stage 0/I breast cancer
Makoto Sumazaki et al.
CANCER SCIENCE (2021)
CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy
Z. Zhu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Druggable cancer phosphatases
Julia P. Vainonen et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma
Jitian Li et al.
FRONTIERS IN IMMUNOLOGY (2021)
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia
Richard E. Clark et al.
CANCERS (2021)
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line
Hisham Saafan et al.
CELLS (2021)
The MYC oncogene - the grand orchestrator of cancer growth and immune evasion
Renumathy Dhanasekaran et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Salome Adam et al.
NATURE CANCER (2021)
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala et al.
NATURE REVIEWS CANCER (2021)
Functional repertoire of protein kinases and phosphatases in synaptic plasticity and associated neurological disorders
Raheel Khan et al.
NEURAL REGENERATION RESEARCH (2021)
Downregulation of CIP2A inhibits cancer cell proliferation and vascularization in renal clear cell carcinoma
Hui Gao et al.
BIOMEDICAL PAPERS-OLOMOUC (2020)
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers
Caroline C. Farrington et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
Raffaella Pippa et al.
CELLS (2020)
Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer
Wei Chen et al.
CELL COMMUNICATION AND SIGNALING (2020)
Targeting the Wnt/β-catenin signaling pathway in cancer
Ya Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling
Mohd Moin Khan et al.
ISCIENCE (2020)
Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma
Rajab Alzahrani et al.
JOURNAL OF CANCER PREVENTION (2020)
Role of protein phosphatases in the cancer microenvironment
Peter P. Ruvolo
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia
Wenjing Ma et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2019)
Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer
Pengfei Liu et al.
MOLECULES (2019)
CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits
Yang-Ping Shentu et al.
NEUROBIOLOGY OF AGING (2019)
MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A
Ruojing Wei et al.
ONCOLOGY LETTERS (2019)
Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis
Mohamed Elgendy et al.
CANCER CELL (2019)
Inhibition of CBP/β-catenin and porcupine attenuates Wnt signaling and induces apoptosis in head and neck carcinoma cells
Robert Kleszcz et al.
CELLULAR ONCOLOGY (2019)
CIP2A overexpression in Taiwanese oral cancer patients
Bharath Kumar Velmurugan et al.
CANCER MANAGEMENT AND RESEARCH (2019)
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer
Michiel Remmerie et al.
FRONTIERS IN ONCOLOGY (2019)
Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis
Yanhong Li et al.
DISEASE MARKERS (2019)
Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance
Xiaolin Wang et al.
MEDICINE (2019)
Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis
Feifei Feng et al.
ONCOLOGY LETTERS (2019)
HP-1 inhibits the progression of ccRCC and enhances sunitinib therapeutic effects by suppressing EMT
Liang Fang et al.
CARBOHYDRATE POLYMERS (2019)
The red wine component ellagic acid induces autophagy and exhibits anti-lung cancer activity in vitro and in vivo
Jing Duan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer
Peng Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities
Piao Huang et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Invstigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth
Adele P. Williams et al.
TRANSLATIONAL ONCOLOGY (2019)
Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer
Jiang Yin et al.
JOURNAL OF CANCER (2019)
Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma
Xue Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer
Juanli Ji et al.
CANCER BIOMARKERS (2018)
Driving CARs on the uneven road of antigen heterogeneity in solid tumors
Nan Chen et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Otto Kauko et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Ethoxysanguinarine inhibits viability and induces apoptosis of colorectal cancer cells by inhibiting CIP2A
Lan Jin et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer
Xuewen Liu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells
Yonghao Tian et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme
Shanshan Qin et al.
MOLECULAR CARCINOGENESIS (2018)
CIP2A is overexpressed in human endometrioid adenocarcinoma and regulates cell proliferation, invasion and apoptosis
Ning Yu et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
Evan F. Garner et al.
SCIENTIFIC REPORTS (2018)
Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer
Eva-Maria Birkman et al.
CANCER MEDICINE (2018)
Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back
Jukka Westermarck
FEBS JOURNAL (2018)
Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis
Yunfei Zhang et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2018)
ER stress-related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer
Chun-Yu Liu et al.
MOLECULAR ONCOLOGY (2018)
Euxanthone suppresses tumor growth and metastasis in colorectal cancer via targeting CIP2A/PP2A pathway
Ning Wang et al.
LIFE SCIENCES (2018)
Protein phosphatase 2A as therapeutic targets in various disease models
Rathinasamy Baskaran et al.
LIFE SCIENCES (2018)
Prognostic significance of CIP2A expression in solid tumors: A meta-analysis
Min Tang et al.
PLOS ONE (2018)
miR-548b-3p Regulates Proliferation, Apoptosis, and Mitochondrial Function by Targeting CIP2A in Hepatocellular Carcinoma
Lin Lin et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1
H. Liu et al.
ONCOGENE (2017)
EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells
Chun-Yu Liu et al.
EUROPEAN JOURNAL OF CANCER (2017)
CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin
Fengbin Gao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway
Jinhui Wu et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2017)
Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells
Xuewen Liu et al.
ONCOLOGY REPORTS (2017)
High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis
Geqi Cha et al.
ONCOTARGETS AND THERAPY (2017)
MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A
Shasha Zhao et al.
ONCOLOGY LETTERS (2017)
Reproducibility in Cancer Biology: Small molecules remain on target for c-Myc
Linchong Sun et al.
ELIFE (2017)
The role of CIP2A in cancer: A review and update
Saiedeh Razi Soofiyani et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Overexpression of CIP2A is associated with poor prognosis in multiple myeloma
Xuewen Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition
Chun-Yu Liu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer
Isamu Hoshino et al.
CANCER SCIENCE (2017)
Overexpression of CIP2A promotes bladder cancer progression by regulating EMT
X. Pang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase
Jaya Sangodkar et al.
FEBS JOURNAL (2016)
Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma
Johannes Routila et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2016)
CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway
Juan Liu et al.
TUMOR BIOLOGY (2016)
CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma
Ting-Ting Chao et al.
APMIS (2016)
A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer
Hong-Fei Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells
Qingxia Zhao et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
CIP2A regulates proliferation and apoptosis of multiple myeloma cells
Zhuanzhen Zheng et al.
MOLECULAR MEDICINE REPORTS (2016)
Gambogenic acid induces proteasomal degradation of CIP2A and sensitizes hepatocellular carcinoma to anticancer agents
Xian-Jun Yu et al.
ONCOLOGY REPORTS (2016)
Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/Adriamycin cells
Fen Cai et al.
ONCOLOGY REPORTS (2016)
HDAC1 controls CIP2A transcription in human colorectal cancer cells
Manjola Balliu et al.
ONCOTARGET (2016)
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
Chun-Yu Liu et al.
ONCOTARGET (2016)
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine
Peng Xu et al.
ONCOTARGET (2016)
Cancerous Inhibitor of PP2A Silencing Inhibits Proliferation and Promotes Apoptosis in Human Multiple Myeloma Cells
Xi Yang et al.
BIOMED RESEARCH INTERNATIONAL (2016)
The broken Off switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance
Peter P. Ruvolo
BBA CLINICAL (2016)
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy
Kuen-Feng Chen et al.
BMC CANCER (2015)
CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer
Bo Peng et al.
BMC CANCER (2015)
CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression
Yi Wu et al.
CANCER LETTERS (2015)
MiR-218 Mediates tumorigenesis and metastasis: Perspectives and implications
Ying-fei Lu et al.
EXPERIMENTAL CELL RESEARCH (2015)
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Eva Barragan et al.
HAEMATOLOGICA (2015)
Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients
C. M. Lucas et al.
LEUKEMIA (2015)
Overexpression of CIP2A in clear cell renal cell carcinoma promotes cellular epithelial-mesenchymal transition and is associated with poor prognosis
Qizhen Tang et al.
ONCOLOGY REPORTS (2015)
Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin
Rajash Pallai et al.
TUMOR BIOLOGY (2015)
Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A
Ting-Ting Chao et al.
ONCOTARGET (2015)
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations
Anchit Khanna et al.
ONCOTARGET (2015)
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Eva Barragan et al.
HAEMATOLOGICA (2015)
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
Vivi Ann Florenes et al.
CANCER MEDICINE (2015)
被撤回的出版物: Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy (Retracted article. See April, 2017)
Jinming Huang et al.
TUMOR BIOLOGY (2015)
CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance
Sami Ventela et al.
ONCOTARGET (2015)
Expression and prognostic significance of CIP2A in cutaneous malignant melanoma
Feng Shi et al.
BIOMARKERS (2014)
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin
L. Wei et al.
CANCER GENE THERAPY (2014)
Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer
Zi Liu et al.
CARCINOGENESIS (2014)
Estradiol enhances CIP2A expression by the activation of p70 S6 kinase
Yeon A. Choi et al.
ENDOCRINE-RELATED CANCER (2014)
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Protein Is Involved in Centrosome Separation through the Regulation of NIMA (Never In Mitosis Gene A)-related Kinase 2 (NEK2) Protein Activity
Ae Lee Jeong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism
Hsei-Wei Wang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ
Hyun Min Jung et al.
MOLECULAR CANCER (2014)
Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth
Na Liu et al.
MOLECULAR CANCER (2014)
Role of CIP2A in the antitumor effect of bortezomib in colon cancer
Yayun Ding et al.
MOLECULAR MEDICINE REPORTS (2014)
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation
Cheng-Yi Wang et al.
LUNG CANCER (2014)
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus
Juandong Wang et al.
MEDICAL ONCOLOGY (2014)
CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer
Ningjing Lei et al.
ONCOLOGY REPORTS (2014)
CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion
Mo Zhai et al.
TUMOR BIOLOGY (2014)
Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis
Xinxin Liu et al.
TUMOR BIOLOGY (2014)
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A
H-C Yu et al.
CELL DEATH & DISEASE (2014)
Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells
Zi Liu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands
Pradip De et al.
ONCOTARGET (2014)
TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway
Ting-Ting Chao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells
Chun-Yu Liu et al.
BREAST CANCER RESEARCH (2014)
Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma
Hui-Chuan Yu et al.
BIOCHEMICAL PHARMACOLOGY (2013)
CIP2A Modulates Cell-Cycle Progression in Human Cancer Cells by Regulating the Stability and Activity of Plk1
Jae-Sung Kim et al.
CANCER RESEARCH (2013)
Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells
Anchit Khanna et al.
CANCER RESEARCH (2013)
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells
Chun-Yu Liu et al.
HAEMATOLOGICA (2013)
Expression and biological role of CIP2A in human astrocytoma
Fuxin Yi et al.
MOLECULAR MEDICINE REPORTS (2013)
Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition
Duen-Ren Hou et al.
MOLECULES (2013)
CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma
Yijun Xue et al.
MEDICAL ONCOLOGY (2013)
CIP2A expression and prognostic role in patients with esophageal adenocarcinoma
Tuomo Rantanen et al.
MEDICAL ONCOLOGY (2013)
Clinical implications of CIP2A protein expression in breast cancer
Guangzhe Yu et al.
MEDICAL ONCOLOGY (2013)
Fusogenic-Oligoarginine Peptide-Mediated Delivery of siRNAs Targeting the CIP2A Oncogene into Oral Cancer Cells
Liliana Cantini et al.
PLOS ONE (2013)
CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression
Armin Wiegering et al.
PLOS ONE (2013)
CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma
Lei Wang et al.
TUMOR BIOLOGY (2013)
PP2A-Mediated Anticancer Therapy
Weibo Chen et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2013)
Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues
Pinzhu Huang et al.
BIOMARKERS (2012)
Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity
Kuen-Feng Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
CIP2A overexpression is associated with c-Myc expression in colorectal cancer
Camilla Böckelman et al.
CANCER BIOLOGY & THERAPY (2012)
Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A
Chao-Yuan Huang et al.
CANCER LETTERS (2012)
CIP2A Is Highly Expressed in Hepatocellular Carcinoma and Predicts Poor Prognosis
Hui He et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2012)
CIP2A Is a Predictor of Poor Prognosis in Colon Cancer
Hao-Wei Teng et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2012)
CIP2A is overexpressed in esophageal squamous cell carcinoma
Wei Qu et al.
MEDICAL ONCOLOGY (2012)
CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis
Peng Xu et al.
MEDICAL ONCOLOGY (2012)
Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation
D. P. Mathiasen et al.
ONCOGENE (2012)
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells
Yu-Chin Lin et al.
ORAL ONCOLOGY (2012)
CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis
Yuanyuan Fang et al.
TUMOR BIOLOGY (2012)
CIP2A protein expression in high-grade, high-stage bladder cancer
Lisa P. Huang et al.
CANCER MEDICINE (2012)
Ets1 and Elk1 transcription factors regulate Cancerous Inhibitor of Protein phosphatase 2A expression in cervical and endometrial carcinoma cells
Rajash Pallai et al.
TRANSCRIPTION-AUSTIN (2012)
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Ling-Ming Tseng et al.
BREAST CANCER RESEARCH (2012)
CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis
Qian-Ze Dong et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis
Weihong Liu et al.
AUTOIMMUNITY REVIEWS (2011)
Prognostic role of CIP2A expression in serous ovarian cancer
C. Bockelman et al.
BRITISH JOURNAL OF CANCER (2011)
Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival
J. Ren et al.
BRITISH JOURNAL OF CANCER (2011)
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer
C. Bockelman et al.
BRITISH JOURNAL OF CANCER (2011)
Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein
Juan Liu et al.
GYNECOLOGIC ONCOLOGY (2011)
CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation
J. Wang et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2011)
A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases
Chong Xie et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells
Anchit Khanna et al.
PLOS ONE (2011)
Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer
Liang Ma et al.
PLOS ONE (2011)
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors
Jian-Ying Zhang et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2010)
CIP2A expression is increased in prostate cancer
Markku H. Vaarala et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
K-F Chen et al.
ONCOGENE (2010)
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Anchit Khanna et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Autoantibodies to tumor-associated antigens: reporters from the immune system
Eng M. Tan et al.
IMMUNOLOGICAL REVIEWS (2008)
CIP2A inhibits PP2A in human malignancies
Melissa R. Junttila et al.
CELL (2007)
Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens
FD Shi et al.
PROSTATE (2005)
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer
LS Hoo et al.
ONCOGENE (2002)
Share Paper
